Abstract
It is known that potassium channels are important for cell proliferation. HERG, a potassium channel protein, is a transmembrane protein, which increases in concentration on the cell surface of cancer cells. Apart from cancer cells, this protein is found only in the brain & heart tissue, in very low number. The proliferation of cells in cancer is dependent on activation of this protein, and it has been noted that blocking of this protein with drug molecule, helps inhibit the proliferation of the cells further. The current work aims to study the binding potentials of κ-PVIIA, conotoxin isolated from Conus purpurascens venom with HERG K+ channel of tumor cells, where HERG mutation has been noted. The toxin under consideration i.e. κ-conotoxins-PVIIA (κ-PVIIA) is a 27 residue peptide. The docking studies suggest that the conotoxin binds stably to the HERG protein. The study shows that the peptide interacts with the charged extracellular unit of the HERG protein, i.e. the extracellular portion of the S5 domain named S5-P extracellular linker. Study of binding of toxins of similar origin, with normal potassium channels has been studied in silico. Further, wet laboratory work needs to be conducted for development of a drug molecule from this toxin, to treat some number of cancers.
Keywords: Conotoxin, Potassium Channel, Anti-cancer, Drug, Docking
Current Topics in Medicinal Chemistry
Title:Conotoxins: Review and Docking Studies to determine potentials of Conotoxin as an Anticancer Drug Molecule
Volume: 12 Issue: 8
Author(s): Kirtan Dave and Anasuya Lahiry
Affiliation:
Keywords: Conotoxin, Potassium Channel, Anti-cancer, Drug, Docking
Abstract: It is known that potassium channels are important for cell proliferation. HERG, a potassium channel protein, is a transmembrane protein, which increases in concentration on the cell surface of cancer cells. Apart from cancer cells, this protein is found only in the brain & heart tissue, in very low number. The proliferation of cells in cancer is dependent on activation of this protein, and it has been noted that blocking of this protein with drug molecule, helps inhibit the proliferation of the cells further. The current work aims to study the binding potentials of κ-PVIIA, conotoxin isolated from Conus purpurascens venom with HERG K+ channel of tumor cells, where HERG mutation has been noted. The toxin under consideration i.e. κ-conotoxins-PVIIA (κ-PVIIA) is a 27 residue peptide. The docking studies suggest that the conotoxin binds stably to the HERG protein. The study shows that the peptide interacts with the charged extracellular unit of the HERG protein, i.e. the extracellular portion of the S5 domain named S5-P extracellular linker. Study of binding of toxins of similar origin, with normal potassium channels has been studied in silico. Further, wet laboratory work needs to be conducted for development of a drug molecule from this toxin, to treat some number of cancers.
Export Options
About this article
Cite this article as:
Dave Kirtan and Lahiry Anasuya, Conotoxins: Review and Docking Studies to determine potentials of Conotoxin as an Anticancer Drug Molecule, Current Topics in Medicinal Chemistry 2012; 12 (8) . https://dx.doi.org/10.2174/156802612800166765
DOI https://dx.doi.org/10.2174/156802612800166765 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Emergence of Immune-checkpoint Inhibitors in Colorectal Cancer Therapy
Current Drug Targets Application of Microdialysis in Clinical Pharmacology
Current Clinical Pharmacology Shared Signaling Pathways Between Endocrine and Immune System Receptors: The Model of Gamma Chain
Current Signal Transduction Therapy Survivin Modulators: An Updated Patent Review (2011 - 2015)
Recent Patents on Anti-Cancer Drug Discovery The Vitamin D Saga: Breaking Dawn
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Highly Efficient, Chemoselective Syntheses of 2-Methoxy-4-substituted Pyrimidines
Letters in Organic Chemistry Overview of Molecular Signal Transduction of Malignant Gliomas and Correlation with Responses to Targeted Therapy Recent advances in Molecular Characterization of Glioblastoma
Current Signal Transduction Therapy Stem Cell Differentiation Stage Factors from Zebrafish Embryo: A Novel Strategy to Modulate the Fate of Normal and Pathological Human (Stem) Cells
Current Pharmaceutical Biotechnology Toxicological Effects of Dietary Biogenic Amines
Current Nutrition & Food Science Hecogenin Acetate Inhibits Reactive Oxygen Species Production and Induces Cell Cycle Arrest and Senescence in the A549 Human Lung Cancer Cell Line
Anti-Cancer Agents in Medicinal Chemistry PEDF as an Emerging Therapeutic Candidate for Osteosarcoma
Current Cancer Drug Targets Familial Mutations and Post-translational Modifications of UCH-L1 in Parkinson's Disease and Neurodegenerative Disorders
Current Protein & Peptide Science Red Blood Cells as Modulators of T Cell Growth and Survival
Current Pharmaceutical Design Direct Evidence on the Immune-Mediated Spontaneous Regression of Human Cancer: An Incentive for Pharmaceutical Companies to Develop a Novel Anti-Cancer Vaccine
Current Pharmaceutical Design Editorial [Human Methylome Variation and the Rise of Epigenetic Epidemiology]
Current Pharmacogenomics and Personalized Medicine Fatty Acid (FA) Compositions and Trans Content of Frequently Consumed Edible Oils and Fats from Iran’ Market
Current Nutrition & Food Science Rapid UPLC Tandem Triple Quadrupole Mass Spectrometry Method for Determination of Regorafenib in Plasma
Current Analytical Chemistry Biological Relevance of DNA Polymerase Beta and Translesion Synthesis Polymerases to Cancer and its Treatment
Current Molecular Pharmacology Resistance to Anti-VEGF Agents
Current Pharmaceutical Design Targeting ADAM17 Sheddase Activity in Cancer
Current Drug Targets